GRAL GRAIL, LLC
Company Analysis
Latest News
🔴 GRAIL is trading 4.15% down today with no clear company-specific catalyst
GRAIL is trading at $76.68, down -4.15%, with no clear company-specific catalyst directly explaining the decline. • No new GRAIL announcement dated August 31,...
🔴 GRAIL falls 4.3% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Casdin Capital more than doubles its stake in cancer detection firm GRAIL (GRAL)
Life sciences investor Casdin Capital significantly increased its position in early cancer detection company GRAIL (GRAL), more than doubling its share count...
🟢 GRAIL is trading 4.24% up in after-hours trading amid stronger technology sentiment after Nvidia and Salesforce results
GRAIL is trading 4.24% up in after-hours trading at $86.00, primarily aligned with stronger broader-market and technology sentiment following Nvidia and...
🟢 GRAIL is trading 4.55% up today
GRAIL is trading 4.55% up now at $83.21 after a volatile week, with no clear company-specific catalyst identified for August 27, 2026. - Latest disclosed...
🔴 GRAIL is trading 4.6% down today with no clear company-specific catalyst
GRAIL is trading 4.6% down now at $78.75, with no clear company-specific announcement identified to explain the decline. - Shares rose 7.78% to $82.54 on...
🟢 GRAIL rises 5.3% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
GRAIL Faces Misconduct Probe, Following Failed NHS-Galleri Cancer Trial
A law firm is investigating GRAIL, Inc. officers and directors for potential wrongdoing on behalf of long-term investors. This probe follows a lawsuit alleging...
🟢 GRAIL is trading 5% up today
GRAIL is trading 5.3% up at $77.88, with no clear company-specific catalyst identified for August 20, 2026. - The latest material development is the FDA’s...
🟢 GRAIL is trading 4.8% up today as immediate catalyst remains unclear
GRAIL is trading 4.8% up at $77.48, while the immediate catalyst remains unclear. - No new company-specific announcement dated August 20, 2026, was identified...
🟢 GRAIL is trading 6.2% up today amid biotech rally after positive Moderna cancer-vaccine results
GRAIL is trading 6.2% up at $75.30, significantly outperforming its August 18 close of $70.89 amid biotech-sector strength following positive Moderna...
🟢 GRAIL is trading 4.2% up today amid optimism over FDA’s September 23 Galleri review
GRAIL is trading at $70.73, up 4.21%, as investors focus on the FDA’s scheduled September 23 advisory committee review of Galleri’s premarket approval...
🔴 GRAIL is trading 4% down today after three advancing sessions
GRAIL is trading 4.01% down now at $72.45, reversing after three consecutive advancing sessions; no reliable source identifies a new company-specific...
GRAIL's Revenue Beat Couldn't Mask a Pricing Problem — Can the Cancer-Detection Pioneer Grow Without Giving Away the Store?
Shares of GRAIL plunged 8.3% to $68.00 in after-hours trading following a second-quarter report that, on the surface, looked strong — revenue of $44.7 million...
🟢 GRAIL is trading 5% up today after FDA plans September Galleri advisory meeting
GRAIL is trading 5.47% up now at $66.87 after the FDA announced plans for a September advisory committee meeting on Galleri, its multi-cancer screening...
🔴 GRAIL is trading 11.37% down today after adjusted EBITDA losses widened
GRAIL is trading 11.37% down now at $65.75 after investors reacted negatively to its August 5 earnings and wider adjusted EBITDA losses. - Revenue reached...
🔴 GRAIL is trading 8.67% down today after adjusted EBITDA losses widened
GRAIL is trading 8.67% down now at $67.75 after investors focused on widening adjusted EBITDA losses following its August 5, 2026 earnings release. -...
🔴 GRAIL is trading 5.5% down today as initial earnings gains reverse on pricing pressure concerns
GRAIL is trading at $70.12 (-5.47%) in pre-market as the initial positive reaction to its Q2 earnings report reversed due to concerns over monetization. • The...
🔴 GRAIL is trading 8.3% down today on weak commercial mix and guidance tone
GRAIL is trading at $68.00 (-8.33%) following its second-quarter update, as investors focus on a weaker-than-expected commercial mix and cautious guidance...
GRAIL, LLC Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
For the second quarter of 2026, analysts expect GRAIL to report a consensus revenue of $42.39 million and a loss per share of $2.66, with the stock currently...